SELLAS Life Sciences Group, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
31.98 |
21.68 |
55.53 |
119.47 |
293.31 |
| Przychód Δ r/r |
0.00% |
inf% |
-32.21% |
156.11% |
115.16% |
145.51% |
| Przychód (min) |
0.00 |
31.98 |
21.68 |
55.53 |
119.47 |
293.31 |
| Przychód (max) |
0.00 |
31.98 |
21.68 |
55.53 |
119.47 |
293.31 |
| EBITDA (średnia) |
0.00 |
-6.40 |
-4.34 |
-11.11 |
-23.89 |
-58.66 |
| EBIT (średnia) |
0.00 |
-6.40 |
-4.34 |
-11.11 |
-23.89 |
-58.66 |
| EBIT % |
0.00% |
-20.00% |
-20.00% |
-20.00% |
-20.00% |
-20.00% |
| Zysk netto (średni) |
-328.45 |
-193.81 |
-229.51 |
-134.65 |
85.68 |
1,236.29 |
| Zysk netto % |
-inf% |
-606.01% |
-1058.62% |
-242.49% |
71.72% |
421.50% |
| EPS (średnia) |
-0.54 |
-0.32 |
-0.38 |
-0.25 |
0.14 |
2.02 |
| Liczba analityków (Przychody) |
0 |
1 |
2 |
2 |
1 |
1 |
| Liczba analityków (EPS) |
2 |
2 |
3 |
3 |
1 |
1 |
| symbol |
SLS |
SLS |
SLS |
SLS |
SLS |
SLS |